CLINICAL_TRIALS
trial_result
· 2010-09-14
Clinical Trial Update: Dose Ranging Study With LT, Monotherapy, PPAR [Phase 2, Phase 3]
Summary
Bristol-Myers Squibb completed a dose-ranging study (Phase 2/Phase 3) of LT as monotherapy targeting PPAR in type 2 diabetes mellitus.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Diabetes Mellitus II | Phase 2, Phase 3 | Status: COMPLETED